# Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

> **NCT05814666** · PHASE2 · TERMINATED · sponsor: **Flamingo Therapeutics NV** · enrollment: 69 (actual)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** Danvatirsen
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05814666
- **Lead sponsor:** Flamingo Therapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-30
- **Primary completion:** 2025-08-14
- **Final completion:** 2025-08-14
- **Target enrollment:** 69 (ACTUAL)
- **Why stopped:** Interim analysis was negative
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814666, "Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05814666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*